Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

Ramosetron and palonosetron are more recently developed 5-hydroxytryptamine type 3 receptor antagonists and this randomized double blind study was designed to compare efficacy of ramosetron and palonosetron to prevent postoperative nausea and vomiting. Investigator hypothesized that palonosetron would have stronger and longer lasting antiemetic effect compared with ramosetron and evaluated the patients for the first 48 hours after surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Incheon St.Mary's Hospital
• Treatments: Palonosetron; Ramosetron

Criteria

Inclusion Criteria:

• ASA Physical Status 1 or 2

• Elective gynaecological laparoscopic surgery of ≥ 1h duration

Exclusion Criteria:

• Anti-emetics, steroids, or psychoactive medications within 24 h of study initiation

• Vomiting or retching in the 24 h preceding surgery

• Cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry

• Ongoing vomiting from gastrointestinal disease